Swiss pharma company pays US$5.5b for US capsule maker
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[ZURICH] Swiss pharmaceuticals and life sciences group Lonza said Thursday it had bought US capsule maker Capsugel for US$5.5 billion as it focuses more on health care.
The deal includes refinancing Capsugel's existing debt of US$2 billion and is set to be finalised by the second quarter of 2017, Lonza said in a statement.
Buying Capsugel "meets Lonza's strategic and financial goals", chief executive Richard Ridinger said in the statement.
"It accelerates our healthcare continuum strategy by giving us broader exposure to the fast-growing pharma and consumer healthcare markets," he added.
Both companies' boards of directors have approved the deal.
Lonza said that within three years it expected to achieve 30 million Swiss francs (S$42.1 million ) per year in operating synergies and 15 million Swiss francs in tax synergies a year.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
Capsugel, which is based in New Jersey, was purchased from Pfizer in 2011 by private equity firm KKR.
AFP
Share with us your feedback on BT's products and services
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Amazon’s MGM Studios gains creative control over ‘James Bond’ franchise
UOB’s Wee Ee Cheong says S$4.9 billion Citi deal ‘paying off’ as Asean push accelerates
In taxing wealth, how far can Singapore push property owners?
